JPMorgan analyst Jessica Fye started shares of Esperion Therapeutics with an Overweight rating and $130 price target. The stock closed yesterday up $3.05 to $84.02. Fye sees a multi-billion dollar sales opportunity for Esperion's lead asset, ETC-1002, in studies to treat high cholesterol.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here